COMMUNIQUÉS West-GlobeNewswire

Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
13/10/2025
Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovation LONDON and PHILADELPHIA, Oct. 13, 2025 (GLOBE NEWSWIRE [...]
Press release: Transparency Notification from Shareholder
13/10/2025
Transparency Notification from Shareholder Ghent, Belgium – 13 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, oral therapeutics for [...]
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET UTRECHT, The [...]
EarlyHealth Group acquiert CYB3R, l’entreprise de cybersécurité à la croissance la plus rapide du Golfe
13/10/2025
DUBAÏ, Émirats arabes unis, 13 oct. 2025 (GLOBE NEWSWIRE) -- EarlyHealth Group, une société internationale du secteur des services pharmaceutiques et des solutions pour les sciences de la vie, a acquis une participation [...]
New Study Confirms Stress-Reduction Benefits of Natural Remedies’ Ashwa.30
13/10/2025
BANGALORE, India, Oct. 13, 2025 (GLOBE NEWSWIRE) -- A new study conducted by Clinical Research Australia reinforces the stress-reducing potential of Natural Remedies ’ Ashwa.30 , a next-generation ashwagandha extract. [...]
General Oncology to Present Preliminary Phase 1 Results from SHARON Trial in Patients with BRCA/PALB2-mutated Pancreatic and Breast Cancer at ESMO 2025
13/10/2025
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc. (“General Oncology” or the “Company”), a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers [...]
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
13/10/2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the [...]
PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project
13/10/2025
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio ( [...]
Humanitarian Nonprofit Human Appeal USA to Host National Comedy Tour
13/10/2025
Joy and Impact Unleashed as Comedy Tour Funds Critical Relief for Those in Need MISSION VIEJO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Humanitarian aid nonprofit, Human Appeal USA , is kicking off their national [...]
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
13/10/2025
HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq [...]
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
13/10/2025
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA, [...]
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
13/10/2025
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and [...]
Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
13/10/2025
HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the [...]
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
13/10/2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
ProQR to Participate in Upcoming Investor Conferences in October 2025
13/10/2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
13/10/2025
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, [...]
Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit
13/10/2025
NEWTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today [...]
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
13/10/2025
Presentation will cover two-year clinical efficacy, immunogenicity and safety data Data will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights [...]

Pages